Curevax

CureVax is a biotechnology company focused on developing innovative cancer immunotherapeutic technologies, particularly for melanoma treatment. The company employs a method that involves sampling a patient's tumor cells, cultivating them in a laboratory, and then inducing a specific form of destruction to reveal the cancer’s vulnerabilities. This process involves infecting the cultured tumor cells with a live vaccinia virus, which causes the cells to burst and release contents that can be recognized by the immune system. The resulting material, known as viral oncolysate, is then reintroduced into the patient to stimulate an immune response against the cancer. By leveraging this approach, CureVax aims to enhance the effectiveness of existing medical and surgical treatments, ultimately improving patient survival rates and quality of life.